Identity
PNC-27 combines a p53-derived binding domain with a membrane-penetrating peptide.
Selected study only; not a complete clinical review.
Peptide library
PNC-27
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Tumor-cell membrane effects in culture are preclinical. Selectivity in a cell assay does not establish human tumor response, survival, systemic exposure or acceptable toxicity.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Cultured breast-cancer and untransformed epithelial cells.
What the sources found
Intact peptide was associated with cancer-cell membrane lysis in vitro; clinical cancer treatment benefit was not tested.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
PNC-27 combines a p53-derived binding domain with a membrane-penetrating peptide.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- Selective effects in cultured cells cannot establish systemic human safety.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Intact peptide was associated with cancer-cell membrane lysis in vitro; clinical cancer treatment benefit was not tested.
Selected study only; not a complete clinical review.
Adverseeffects
Selective effects in cultured cells cannot establish systemic human safety.
Selected study only; not a complete clinical review.
References
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. 2010.
PMID: 20182728
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.